Metalabs announced through its earnings release on the 27th that it recorded sales of 81.4 billion won in 2025. This represents an increase of approximately 112% compared to sales of 38.4 billion won in 2024. The company posted an operating loss of 7.1 billion won.
A company official said, "Sales increased significantly due to the new businesses promoted in 2025 and the inclusion of consolidated subsidiaries," adding, "The operating loss was due to bad debt expenses, and performance is expected to improve in 2026."
The company plans to make 2026 the first year of its performance turnaround, based on the expanded sales. To this end, it intends to establish a foundation for generating operating profit by streamlining its business structure, strengthening cost control, and optimizing organizational operations.
In addition, to strengthen its artificial intelligence (AI)-based digital healthcare capabilities, the company plans to reinforce the customer relationship management (CRM) solution business for non-reimbursable specialized hospitals, such as those for hair loss and weight loss, which is being carried out through its subsidiary Meta S&C, and to advance it into an AI-based business model by linking it with its medical data analysis and medical big data businesses.
A Metalabs representative stated, "If 2025 was the year we secured the foundation for external growth, 2026 will be the first year in which we establish a profitability-centered management structure," adding, "We will build a sustainable growth structure by strengthening the competitiveness of our core businesses."
Meanwhile, KOSPI-listed subsidiary Metacare is expanding its distribution network, focusing on the supply of pharmaceuticals and medical devices to medical institutions. The company recorded sales of 21.9 billion won and operating profit of 2.5 billion won in 2025.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
